Status | Study |
Recruiting |
Study Name: The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma Condition: Pleural Neoplasms Mesothelioma Pneumothorax Date: 2012-03-23 Interventions: Other: Blood sampling Biologic |
Completed |
Study Name: An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Condition: Parathyroid Carcinoma Hypercalcemia Primary Hyperparathyro Date: 2011-10-25 Interventions: Drug: Cinacalcet HCl Oral administration |
Terminated |
Study Name: High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma Condition: Parathyroid Adenomas Date: 2011-02-07 Interventions: Device: High Intensity Focused Ultrasound One or two HIFU sessions |
Terminated |
Study Name: Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma Condition: Hyperparathyroidism Date: 2010-10-14 Interventions: Procedure: C11-Choline PET/CT |
Recruiting |
Study Name: Evaluation of a New CZT System Condition: Parathyroid Adenoma Thyroid Adenoma Date: 2010-03-09 |
Completed |
Study Name: Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure Condition: Primary Parathyroid Adenomas Date: 2010-02-01 Interventions: Device: Ultrasonic ablation device One High Intensity focused ultrasound session before surgery. Use of |
Recruiting |
Study Name: Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms Condition: Endocrine Neoplasms Thyroid Neoplasms Date: 2009-10-30 |
Completed |
Study Name: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Condition: Breast Cancer Hypercalcemia of Malignancy Colon Cancer Date: 2009-05-07 Interventions: Drug: denosumab 120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days |
Terminated |
Study Name: Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas Condition: Parathyroid Neoplasm Parathyroid Diseases Date: 2008-03-12 |
Completed |
Study Name: Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Condition: Melanoma Soft Tissue Sarcoma Parathyroid Carcinoma Date: 2007-12-18 Interventions: Drug: Dacarbazine and bortezomib Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarba |